Table 3.
Comparison between the pcos phenotypes
| HA1 + OD2 + PCO3 (n=111) | HA1 + OD2 (n=18) | HA1 + PCO3 (n=29) | OD2 + PCO3 (n=6) | χ2 | P | ||
|---|---|---|---|---|---|---|---|
| Clomiphene response | Clomiphene resistant (n=88) | 72 (64.86%) | 7 (38.89%) | 8 (27.59%) | 1 (16.67%) | 18.414 | 0.000 |
| Clomiphene sensitive (n=76) | 39 (35.14%) | 11 (61.11%) | 21 (72.41%) | 5 (83.33%) | |||
| Endometrial hyperplasia | Present (n=13) | 11 (9.9%) | 0 (0%) | 1 (3.45%) | 1 (16.67%) | 3.573 | 0.311 |
| Absent (n=151) | 100 (90.1%) | 18 (100%) | 28 (96.55%) | 5 (83.33%) | |||
| Metabolic syndrome | Present (n=40) | 31 (27.93%) | 2 (11.11%) | 5 (17.24%) | 2 (33.33%) | 3.538 | 0.316 |
| Absent (n=124) | 80 (72.07%) | 16 (88.89%) | 24 (82.76%) | 4 (66.67%) | |||
| Blood Sugar abnormalities | Normal (n=87) | 51 (45.94%) | 12 (66.67%) | 20 (68.96%) | 4 (66.67%) | 9.504 | 0.147 |
| Impaired glucose tolerance (n=66) | 51 (45.94%) | 5 (27.78%) | 9 (31.03%) | 1 (16.67%) | |||
| Overt Diabetes Mellitus (n=11) | 9 (8.1%) | 1 (5.55%) | 0 (0%) | 1 (16.67%) | |||
| Body Mass Index in kg/m2 | <18.5 (n=3) | 1 (0.9%) | 0 (0%) | 2 (6.90%) | 0 (0%) | 18.074 | 0.034 |
| 18.5-23 (n=37) | 20 (18.02%) | 4 (22.22%) | 10 (34.48%) | 3 (50%) | |||
| 23-27.5 (n=69) | 44 (39.64%) | 9 (50%) | 13 (44.83%) | 3 (50%) | |||
| >27.5 (n=55) | 46 (41.44%) | 5 (27.78%) | 4 (13.79%) | 0 (0%) | |||
| Menstrual irregularities (in days) | 24-38 days (n=29) | 1 (0.9%) | 0 (0%) | 28 (96.55%) | 0 (0%) | 157.841 | 0.000 |
| 38-60 days (n=31) | 21 (18.92%) | 7 (38.89%) | 0 (0%) | 3 (50%) | |||
| >60 days (n=104) | 89 (80.18%) | 11 (61.11%) | 1 (3.45%) | 3 (50%) |
1-HA- Hyperandrogenism, 2- OD- Ovulatory Dysfunction, 3- PCO- Polycystic Ovaries